SLC5A2 and congenital rubella syndrome: Taking these results together with the positive effects demonstrated by the sodium-glucose cotransporter 2 (SGLT2) inhibitors at the renal level in terms of decreasing the combined renal outcome, these drugs seem to be promising for treating patients with CRS [78].